178 related articles for article (PubMed ID: 16170194)
1. R-CHOP for mantle cell lymphoma.
Klumpp TR
J Clin Oncol; 2005 Sep; 23(27):6802; author reply 6802-3. PubMed ID: 16170194
[No Abstract] [Full Text] [Related]
2. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
3. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
4. JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab.
Rey J; Belmecheri N; Bouayed N; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
Haematologica; 2007 Oct; 92(10):e101. PubMed ID: 18024364
[No Abstract] [Full Text] [Related]
5. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
[TBL] [Abstract][Full Text] [Related]
6. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of focal segmental glomerulosclerosis in association with mantle cell lymphoma.
Wong CF; Mohteshamzadeh M; Arsalanizadeh B; Dutt T; Shawki H; Khine MM; Rustom R
Ren Fail; 2007; 29(3):363-6. PubMed ID: 17497453
[No Abstract] [Full Text] [Related]
8. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
Tamura S; Ohkawauchi K; Yokoyama Y; Higashidani Y; Daibata M; Hiroi M; Yamamori S; Onishi S
J Gastroenterol; 2004 Oct; 39(10):995-1000. PubMed ID: 15549454
[TBL] [Abstract][Full Text] [Related]
9. Current treatment approaches for mantle-cell lymphoma.
Witzig TE
J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
[TBL] [Abstract][Full Text] [Related]
10. Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Michopoulos S; Petraki K; Matsouka C; Kastritis E; Chrysanthopoulou H; Dimopoulos MA
J Clin Oncol; 2008 Mar; 26(9):1555-7. PubMed ID: 18349408
[No Abstract] [Full Text] [Related]
11. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
Lenz G; Dreyling M; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
[TBL] [Abstract][Full Text] [Related]
12. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Furtado M; Johnson R; Kruger A; Turner D; Rule S
Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
[TBL] [Abstract][Full Text] [Related]
13. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Spina M; Simonelli C; Tirelli U
J Clin Oncol; 2007 Feb; 25(6):e7. PubMed ID: 17308261
[No Abstract] [Full Text] [Related]
15. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma.
Lim SH; Esler WV; Periman PO; Beggs D; Zhang Y; Townsend M
Br J Haematol; 2008 Jul; 142(3):482-4. PubMed ID: 18510683
[No Abstract] [Full Text] [Related]
16. Syngeneic transplant in mantle cell lymphoma: a rare event and review of the literature.
Engman CA; Hill JM; Meehan KR
Clin Adv Hematol Oncol; 2009 May; 7(5):321-3. PubMed ID: 19521320
[No Abstract] [Full Text] [Related]
17. Magnifying endoscopic observation of mantle cell lymphoma in the stomach using the narrow-band imaging system.
Nonaka K; Ishikawa K; Arai S; Shimizu M; Sakurai T; Nishimura M; Nakao M; Sasaki Y; Kita H
Endoscopy; 2010; 42 Suppl 2():E94-5. PubMed ID: 20195984
[No Abstract] [Full Text] [Related]
18. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
19. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
20. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
